Screener
Rhythm Pharmaceuticals, Inc. RYTM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(55,639) | $(49,498) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 23,099 | 12,862 |
| Depreciation and amortization | 252 | 383 |
| Non-cash interest expense | 4,577 | 5,408 |
| Non-cash accretion & amortization of short-term investments | (1,436) | (1,787) |
| Non-cash rent expense | 113 | 110 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s net income?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported net income of -$55.64M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s net income changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s net income decreased by 12.4% year-over-year, from -$49.5M to -$55.64M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s net income has grown at a 29.6% compound annual growth rate (CAGR), from -$69.61M to -$196.54M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude